Data from the study indicated that NGX-1998 was well-tolerated and resulted in improved outcomes on validated measures of neuropathic pain. Dose response was demonstrated, and NGX-1998 showed a greater magnitude of response on the pain intensity scale correlating with the concentration of the formulation: 20% > 10% > placebo. In addition, true placebo is an appropriate control for further trials.
In addition to the Company's presentation on NGX-1998, NeurogesX' partner Astellas Pharma Europe Ltd., the European headquarters of Tokyo-based Astellas Pharma Inc., presented a number of posters on Qutenza ® (8% capsaicin patch) at the World Congress on Pain. When combined, the abstracts on the 8% capsaicin patch presented at the conference provide data on over 2,500 treated patients.
One poster was entitled "A Swedish prospective observational multicenter study to evaluate efficacy and safety in patients with peripheral neuropathic pain receiving their first Qutenza ® treatment." The study found that Qutenza ® is an efficacious and tolerable treatment for subgroups of patients with peripheral neuropathic pain. While there are limitations to open label observational studies, researchers concluded the study supports the clinical trials previously reported in patients with PHN and HIV-Associated Peripheral Neuropathy.
Data presented in another poster, "High Concentration Capsaicin Patch Improves Quality of Life in Patients with Neuropathic Non-Diabetic Pain," led to the conclusion that Qutenza ® reduces the intensity of neuropathic pain and significantly increases quality of life in patients who had previously been treated for their neuropathic pain. These results came from a prospective observational study of patients in the Czech Republic.Under its Commercial License Agreement with Astellas, NeurogesX shares in the growing market opportunity for Qutenza in the Astellas territory, which includes the EU, the Middle East and Africa, through ongoing royalties, as well as potential sales milestones. In the United States, Qutenza is approved for the management of PHN. About NeurogesX, Inc. NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients' quality of life.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts